Survival in mice with liver metastases after MBC-005 TREATMENT. by Bryan S. Margulies (21492667)

Subjects:

Inhibitor versus the normalized dose response curves. by Bryan S. Margulies (21492667)

Subjects:

Viscosity assessed using a tuning-fork viscometer. by Bryan S. Margulies (21492667)

Subjects:

Interpolated survival in mice with or without lung metastases. by Bryan S. Margulies (21492667)

Subjects:

The p21 ELISA assay was used to assess the effects of MBC-005 on tumor cell expression of p21. by Bryan S. Margulies (21492667)

Subjects:

Examining cardiac toxicity in HER2-positive breast cancer patients using trastuzumab and its influencing factors at Iran Hospital by Fatemeh Nasri (8290011)

“…<p>Trastuzumab is primarily utilized in the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. This study aimed to investigate the incidence of cardiac toxicity associated with trastuzumab in HER2-positive breast cancer patients at Iran Hospital in 2023, as well as the factors influencing this toxicity. …”

Data Sheet 1_Upright radiotherapy for breast cancer: a pre-clinical study considering photon and proton beam access, plus arm positioning.docx by Gordon Sands (22817087)

“…Beam access was evaluated in multiple regions of the breast while field size and the ISF were measured for the different positions. …”

Participants’ characteristics. by Doris van der Smissen (20536881)

“…Although the (long-term) side-effects of cancer and its treatment can be significant, less is known about the impact on cancer survivors’ participation in daily life. …”

Overview of the main themes and subthemes. by Doris van der Smissen (20536881)

“…Although the (long-term) side-effects of cancer and its treatment can be significant, less is known about the impact on cancer survivors’ participation in daily life. …”

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic... by Hsiang-Ying Wu (22212274)

Apoptosis of MDA-MB-231 cells exposed to tick saliva. by Ana Carolina Prado Sousa (22265110)

Effect of tick saliva on HaCaT cells. by Ana Carolina Prado Sousa (22265110)

Effect of tick saliva on MDA-MB-231 cells. by Ana Carolina Prado Sousa (22265110)

CD74 down-regulation in DC induces pro-inflammatory pathways. by Bianca Pellegrino (20314999)

ASIR prediction from 2020 to 2030 by sex. by Majed M. Ramadan (22379116)

“…</p><p>Results</p><p>The study reveals a significant rise in Age-Standardized Incidence Rates (ASIR) for breast cancer among females in Saudi Arabia from 1990 to 2019, with Oman experiencing the highest increase and Kuwait the highest decrease. …”

Supporting data for “Androgen receptor modulates chemotherapy response in breast cancer” by Chanping You (9067448)

“…</p><p><br></p><p dir="ltr">This study investigated the role of AR in chemotherapy response using two AR-positive breast cancer cell lines. We assessed responses to multiple chemotherapeutic agents—palbociclib, docetaxel, doxorubicin, paclitaxel, and cisplatin. …”

Table 1_Association between neutrophil percentage-to-albumin ratio and breast cancer in adult women in the US: findings from the NHANES.docx by Huikai Liang (21188720)

“…The significance of traits was assessed using mean decrease accuracy (MDA) and mean decrease impurity (MDI). …”

<i>PSAT1</i> gene as a biomarker for targeting triple negative breast cancer in presence of Rapamycin by Mehdi Roshanian Bakhsh (22469915)

“…The outcomes showed that the expression of the <i>decreased</i> gene by Rapamycin among other drugs increased in TNBC subtype compared to the other two subtypes including triple-positive and ER+/PR+. …”

Figure 3 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models by Isabel Quiros-Gonzalez (14952835)

Table 1_Therapeutic potential of Triptolide in inhibiting breast cancer-induced bone destruction – PTHrP as a therapeutic target.docx by Wu Di (11561998)

“…Introduction<p>Bone metastases are a common and severe complication in advanced breast cancer, affecting approximately 65% to 70% of patients and significantly reducing survival time. …”